Merck: This Cancer-Drug Powerhouse Could Be a Core Dividend
A dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
Both funds offer diversification; index funds are passive and typically cheaper. This comparison highlights key differences to inform your choice.
24,304 articlesA dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
A marquee collaboration turned cautionary tale. Explore how a failed merch deal unfolded, what it cost, and how to sh...
In late 2025, Berkshire added 8 million shares to a major energy producer, lifting its portfolio weight. This move po...
Netflix walks away from an $83 billion Warner Bros. deal, freeing capital for expansion and content, lifting the stoc...
XRP’s on-chain activity jumped to about 2.75 million daily transactions, while the token’s price stayed stubbornly ra...
AI-powered venture activity in Q4 2025 shows a notable revival in healthtech, cybersecurity, biotech, and enterprise ...
Oil jumped sharply in March 2026, but USOI investors faced capped upside and ongoing credit risk. The piece explains ...
The Federal Reserve just paused rates, signaling a hold as markets weigh the impact on Social Security income and ret...
A prominent market strategist says investors should their money in gold, proposing a 10% allocation to hedge inflatio...
As housing constraints persist, accessory dwelling units are moving from niche option to mainstream. This piece expla...
Dividend income can be a steady stream, but payouts can change. This article flags three dividend stocks that could c...
This article breaks down Westport’s 2026 earnings landscape, translating the Q1 signals into practical moves for read...